Skip to main content
Article thumbnail
Location of Repository

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential

By Nasser Mikhail

Abstract

Sitagliptin and vildagliptin represent a new class of anti-diabetic agents that enhance the action of incretin hormones through inhibition of dipeptidyl peptidase-4 (DPP-4), the enzyme that normally inactivates incretin hormones. Because of their distinct mechanism of action, DPP-4 inhibitors can be used as add-on therapy to other classes of drugs for treatment of type 2 diabetes. The objective of this review is to critically evaluate clinical trials of sitagliptin and vildagliptin in combination with pioglitazone. The addition of either sitagliptin or vildagliptin to ongoing pioglitazone therapy is associated with reduction in average hemoglobin A1c (HbA1c) levels of approximately 0.7% compared with placebo and 1% compared with baseline after 24 weeks. When started concomitantly in drug-naïve patients, the combination of pioglitazone 30 mg and vildagliptin 100 mg qd reduces HbA1c by 1.9% after 24 weeks, compared with 1.1% with pioglitazone monotherapy. In general, the addition of DPP-4 inhibitors to pioglitazone was well tolerated, did not increase the incidence of hypoglycemia, and did not substantially worsen the weight-gain induced by pioglitazone. The combination of sitagliptpin or vildagliptin with pioglitazone can be a useful therapeutic approach in patients with type 2 diabetes who cannot tolerate metformin or a sulfonylurea

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2663457
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2007). Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care, 30:1979–87. Erratum: Diabetes Care,
    2. (2006). Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care,
    3. (2008). Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulfonylurea. Diabetes Obes Metab. [Epub ahead of print].
    4. (2008). Effi cacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res. [Epub ahead of print].
    5. (2007). Effi cacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes.
    6. (2006). Exenatide: a novel approach for treatment of type 2 diabetes.
    7. (2007). for the Sitagliptin Study 024 Group.
    8. (2008). Incretin mimetics and dipeptidyl peptidase inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opin Investig Drugs,
    9. (2007). Januvia® (sitagliptin phosphate) package insert.
    10. (2006). Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care,
    11. (2008). Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
    12. (2008). Novel combination treatment of type 2 diabetes:
    13. (2007). Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin,
    14. (2008). Safety and effi cacy of sitagliptin in patients with type 2 diabetes and chronic renal insuffi ciency. Diabetes Obes Metab,
    15. (2005). Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macrovascular Events): a randomized controlled trial.
    16. (2007). Systemic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.
    17. (2006). The incretin system: glucagon-like peptide1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    18. (2003). The pharmacokinetics of pioglitazone in patients with impaired renal function.
    19. (2007). The role of DPP-4 inhibitors in type 2 diabetes. Patient Care,
    20. (2003). Thiazolidinedione safety and effi cacy in ambulatory patients receiving hemodialysis.
    21. (2003). Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc,
    22. (2004). Twelve- and 52-week effi cacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care,
    23. (2006). Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res,
    24. (2007). Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebocontrolled study. Diabetes Obes Metab,

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.